Electroencephalographic Recovery, Hypnotic Emergence, and the Effects of Metabolite after Continuous Infusions of a Rapidly Metabolized Etomidate Analog in Rats-Reference-Cited by-同舟云学术

Electroencephalographic Recovery, Hypnotic Emergence, and the Effects of Metabolite after Continuous Infusions of a Rapidly Metabolized Etomidate Analog in Rats

Published:2012-05-01 Issue:5 Volume:116 Page:1057-1065
ISSN:0003-3022
Container-title:Anesthesiology
language:en
Short-container-title:

Author:

Pejo Ervin¹,Ge Rile¹,Banacos Natalie²,Cotten Joseph F.³,Husain S. Shaukat⁴,Raines Douglas E.⁵

Affiliation:

1. Research Technologist.

2. Research Student, Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts.

3. Instructor of Anesthesia, Harvard Medical School, Boston, Massachusetts, and Assistant Anesthetist, Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital.

4. Principal Associate, Harvard Medical School, and Research Associate, Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital.

5. Associate Professor of Anesthesia, Harvard Medical School, and Associate Anesthetist, Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital.

Abstract

Background Methoxycarbonyl etomidate is an ultrarapidly metabolized etomidate analog. It is metabolized to methoxycarbonyl etomidate carboxylic acid (MOC-ECA), which has a hypnotic potency that is 350-fold less than that of methoxycarbonyl etomidate. The authors explored the relationships between methoxycarbonyl etomidate infusion duration, recovery time, metabolite concentrations in blood and cerebrospinal fluid (CSF), and methoxycarbonyl etomidate metabolism in brain tissue and CSF to test the hypothesis that rapid metabolism of methoxycarbonyl etomidate may lead to sufficient accumulation of MOC-ECA in the brain to produce a pharmacologic effect. Methods A closed-loop system with burst suppression ratio feedback was used to administer methoxycarbonyl etomidate infusions of varying durations to rats. After infusion, recovery of the electroencephalogram and righting reflexes were assessed. MOC-ECA concentrations were measured in blood and CSF during and after methoxycarbonyl etomidate infusion, and the in vitro half-life of methoxycarbonyl etomidate was determined in rat brain tissue and CSF. Results Upon termination of continuous methoxycarbonyl etomidate infusions, the burst suppression ratio recovered in a biexponential manner with fast and slow components having time constants that differed by more than 100-fold and amplitudes that varied inversely with infusion duration. MOC-ECA concentrations reached hypnotic concentrations in the CSF with prolonged methoxycarbonyl etomidate infusion and then decreased during a period of several hours after infusion termination. The metabolic half-life of methoxycarbonyl etomidate in brain tissue and CSF was 11 and 20 min, respectively. Conclusion In rats, methoxycarbonyl etomidate metabolism is sufficiently fast to produce pharmacologically active MOC-ECA concentrations in the brain with prolonged methoxycarbonyl etomidate infusion.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Anesthesiology and Pain Medicine

Link

http://pubs.asahq.org/anesthesiology/article-pdf/116/5/1057/257645/0000542-201205000-00016.pdf

Reference21 articles.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural Modification in Anesthetic Drug Development for Prodrugs and Soft Drugs;Frontiers in Pharmacology;2022-07-01

2. Etomidate and its Analogs: A Review of Pharmacokinetics and Pharmacodynamics;Clinical Pharmacokinetics;2021-06-01

3. Preclinical Pharmacokinetics Study of a Novel Intravenous Anesthetic ET-26 Hydrochloride;Current Drug Metabolism;2020-01-23

4. Preclinical safety evaluation of ET‐26 hydrochloride, a novel intravenous anesthetic agent, in beagle dogs;Journal of Applied Toxicology;2019-12-22

5. GABA(A) receptor-targeted drug development -New perspectives in perioperative anesthesia;Expert Opinion on Drug Discovery;2019-04-04